AnaptysBio, Inc. announced that its Phase 2B Trial of ANB032 for atopic dermatitis did not meet its primary and secondary goals, but the drug was well tolerated; the company also expects to have approximately $415 million in cash reserves by year-end 2024, which should fund operations through 2027.